查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2007864

数位疗法平台市场预测至2034年—按产品类型、适应症、技术、应用、最终用户和地区分類的全球分析

Digital Therapeutics Platforms Market Forecasts to 2034 - Global Analysis By Product Type, Indication, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2026 年，全球数位治疗平台市场规模将达到 72 亿美元，并在预测期内以 23.3% 的复合年增长率增长，到 2034 年将达到 385 亿美元。

数位疗法平台是指以软体驱动的医疗干预措施，它透过行动应用程式、主导介面、穿戴式装置整合以及包括虚拟实境在内的身临其境型技术，为患者提供循证治疗方案，帮助他们管理和预防临床疾病。这些平台针对糖尿病、精神疾病、心血管疾病和物质使用障碍等疾病，旨在促进行为改变、疾病自我管理、復健支持和认知疗法。它们可以单独使用，也可以与药物治疗合併使用，并且需要在主要市场获得监管部门的核准。

慢性病负担加重

慢性病负担日益加重是推动需求成长的主要因素，这主要是由于全球人口成长导致糖尿病、心血管疾病和精神疾病的盛行率不断上升，需要持续的推动要素，而不仅仅是偶尔的门诊就诊。保险公司正在扩大数位疗法的承保范围，将其作为传统药物的一种经济有效的补充，从而降低住院率并提高用药依从性。此外，将数位疗法整合到旨在支持员工心理健康的企业健康计画中，也为平台开发人员创造了可观的B2B收入来源。

还款方式不一致

各国医疗体系报销流程的不一致严重限制了数位药品市场的成长。私人保险公司、公共保险机构以及自费市场的碎片化保险政策，使得平台业者的收入难以预测。德国、日本、美国和英国在报销临床证据要求上的差异，导致了成本高昂的平行监管申请。医生处方能力的不足进一步限制了病患的用药途径，并阻碍了保险公司建立标准化的保险覆盖框架。

处方笺数位药物的扩张

随着德国、日本和美国的监管机构正式建立起由临床医生开立处方且医保覆盖的软体医疗干预流程，仅凭处方笺的数位疗法的扩张带来了变革性的商业机会。德国数位医疗设备（DiGA）框架下的核准已树立了支付先例，这将有助于在欧洲市场推广类似的监管模式。与製药业拓展联合行销伙伴关係，使数位疗法开发商能够利用现有的销售网络和支付方关係，加速产品进入市场。

与患者参与和持续使用相关的风险

病患参与度和长期留存率的挑战对数位治疗平台的生存构成根本性的商业性威胁。这是因为临床疗效的验证依赖持续使用，而许多平台难以在最初的推广期后维持使用者使用。高流失率会削弱真实世界疗效数据的生成，而这些数据对于与支付方进行报销谈判至关重要。此外，竞争性的健康应用和通用数位健康工具进一步分散了用户兴趣，使得差异化的临床价值验证对于平台的商业性永续性变得愈发重要。

新冠疫情的影响：

在疫情封锁期间，患者寻求远距疾病管理解决方案，这大大提高了人们对数位疗法市场的认知度，并加速了支付方和医疗服务提供者对相关平台报销的接受度。数位疗法处方与远端医疗的整合为混合医疗模式树立了先例。疫情后，人们对行为医学的需求持续推动数位心理健康疗法的发展，而监管机构则优先考虑简化数位医疗设备的核准流程。

在预测期内，游戏疗法领域预计将成为最大的细分市场。

鑑于游戏化疗法在患者参与度方面展现出优于传统行为介入方式的优势，尤其是在儿童不足过动症（ADHD）、认知復健和神经系统疾病的治疗方面，预计在预测期内，游戏化疗法将占据最大的市场份额。获得FDA已通过核准的游戏化疗法平台已在商业性和临床疗效方面树立了先例。与传统数位介面相比，更高的患者依从性正在推动支付方接受并促使医生开立已通过核准的游戏化疗法产品。

预计在预测期内，糖尿病管理细分市场将呈现最高的复合年增长率。

在预测期内，糖尿病管理领域预计将呈现最高的成长率，这主要受以下因素驱动：2型糖尿病在全球范围内的高发生率、血糖控制不佳导致的医疗保健成本不断上升，以及大量临床证据表明，透过数位化疗法进行生活方式干预能够有效改善健康状况。持续血糖监测和行为指导平台的整合正在催生一种全新的互联医疗产品类型。保险公司日益认识到数位化管理糖尿病患者群体所带来的成本节约优势，从而扩大了保险覆盖范围并增加了处方量。

市占率最大的地区：

在预测期内，北美预计将占据最大的市场份额。这主要得益于美国食品药物管理局 (FDA) 为医疗软体设备设立了全新的 (de novo) 和 510(k) 监管途径，慢性病高发导致支付方兴趣日益浓厚，以及创业投资投资对数位健康平台的强劲投入。总部位于美国的数位疗法公司，包括 Pear Therapeutics 和 Akili Interactive Labs，率先推出了基于处方笺的商业模式。大规模医疗系统将相关技术纳入雇主健康保险福利计画并推行相关项目，也支撑了该地区庞大的市场需求。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于智慧型手机普及率的快速提升、平台接入基础设施的完善、日本和韩国国家级数位医疗投资项目的扩大，以及中国和印度庞大的慢性疾病患者群体。亚太地区各国政府的数位医疗政策和国家级慢性病管理计画正在加速医疗系统层面数位疗法的应用，从而带来显着的市场规模成长。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，我们可以提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需经可行性确认）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章：全球数位治疗平台市场：依产品类型划分

  • 以软体为基础的治疗方法
  • 基于行动应用程式的治疗方法
  • 网路为基础的平台
  • 穿戴式整合治疗设备
  • 游戏治疗方法
  • VR/AR治疗
  • 其他产品类型

第六章 全球数位治疗平台市场：依适应症划分

  • 糖尿病管理
  • 精神疾病
  • 心血管疾病
  • 呼吸系统疾病
  • 物质使用障碍
  • 神经系统疾病

第七章 全球数位治疗平台市场：依技术划分

  • 人工智慧和机器学习
  • 云端运算
  • 巨量资料分析
  • 物联网集成
  • 区块链用于资料安全
  • 预测分析

第八章 全球数位治疗平台市场：按应用划分

  • 治疗/管理
  • 预防医学
  • 復原
  • 慢性病管理
  • 行为疗法
  • 远端监控
  • 其他用途

第九章 全球数位治疗平台市场：依最终用户划分

  • 病人
  • 医疗服务提供方
  • 付款人
  • 雇主
  • 製药公司
  • 研究机构
  • 其他最终用户

第十章：全球数位治疗平台市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十一章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十二章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十三章：公司简介

  • Pear Therapeutics
  • Omada Health
  • Livongo Health
  • Teladoc Health
  • Propeller Health
  • Akili Interactive Labs
  • Click Therapeutics
  • Better Therapeutics
  • Kaia Health
  • Noom Inc.
  • Happify Health
  • Voluntis
  • Biofourmis
  • WellDoc Inc.
  • DarioHealth Corp.
  • ResMed Inc.
  • Philips Healthcare
  • Medtronic plc
Product Code: SMRC34763

According to Stratistics MRC, the Global Digital Therapeutics Platforms Market is accounted for $7.2 billion in 2026 and is expected to reach $38.5 billion by 2034 growing at a CAGR of 23.3% during the forecast period. Digital therapeutics platforms refer to software-driven medical interventions that deliver evidence-based therapeutic functions to patients managing or preventing clinical conditions through mobile applications, web-based interfaces, wearable device integrations, and immersive technologies including virtual reality. These platforms target behavioral modification, disease self-management, rehabilitation support, and cognitive therapy across conditions including diabetes, mental health disorders, cardiovascular diseases, and substance use. They operate independently or adjunctively alongside pharmaceutical treatments and require regulatory clearance in major markets.

Market Dynamics:

Driver:

Chronic Disease Burden Growth

Chronic disease burden growth is a primary demand driver as global populations experience rising prevalence of diabetes, cardiovascular disease, and mental health disorders requiring continuous management beyond episodic clinical visits. Payer organizations are increasingly covering digital therapeutic prescriptions as cost-effective supplements to pharmaceutical treatment, reducing hospitalization rates and improving adherence outcomes. Employer wellness program adoption of digital therapeutics for workforce mental health support is additionally generating substantial B2B revenue streams for platform developers.

Restraint:

Reimbursement Pathway Inconsistency

Reimbursement pathway inconsistency across national healthcare systems materially constrains digital therapeutics market scaling, as fragmented coverage policies between commercial insurers, government payers, and self-pay market segments create uncertain revenue predictability for platform operators. Divergent clinical evidence requirements for reimbursement in Germany, Japan, the U.S., and the UK generate costly parallel regulatory submissions. Limited physician prescribing familiarity further reduces patient access and compounds payer reluctance to establish standard coverage frameworks.

Opportunity:

Prescription Digital Therapeutics Expansion

Prescription digital therapeutics expansion represents a transformative commercial opportunity as regulatory agencies in Germany, Japan, and the United States formalize pathways for clinician-prescribed, reimbursable software-based medical interventions. German DiGA framework approvals have established a payment precedent inspiring parallel regulatory models across European markets. Growing pharmaceutical industry co-commercialization partnerships are enabling digital therapeutic developers to leverage established sales force infrastructure and payer relationships for accelerated market access.

Threat:

Patient Engagement and Retention Risks

Patient engagement and long-term retention challenges represent a fundamental commercial threat to digital therapeutics platform viability, as clinical outcomes evidence depends on sustained usage that many platforms struggle to maintain beyond initial onboarding periods. High dropout rates undermine real-world effectiveness data generation critical for payer reimbursement negotiations. Competing wellness applications and generic digital health tools further fragment user attention, making differentiated clinical value demonstration increasingly essential for platform commercial sustainability.

Covid-19 Impact:

COVID-19 dramatically expanded digital therapeutics market awareness as patients sought remote disease management solutions during lockdown periods, accelerating payer and provider openness to platform reimbursement. Telehealth integration with digital therapeutic prescriptions created hybrid care model precedents. Post-pandemic behavioral healthcare demand has sustained digital mental health therapeutics growth, while regulatory agencies prioritized streamlined digital health device clearance frameworks.

The gaming-based therapeutics segment is expected to be the largest during the forecast period

The gaming-based therapeutics segment is expected to account for the largest market share during the forecast period, due to demonstrated engagement advantages over conventional behavioral intervention interfaces, particularly in pediatric ADHD, cognitive rehabilitation, and neurological condition management. FDA-cleared gaming-based therapeutic platforms have established commercial and clinical validation precedents. Strong patient adherence metrics relative to traditional digital interfaces have driven payer acceptance and physician prescribing adoption for approved gaming therapeutic products.

The diabetes management segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the diabetes management segment is predicted to witness the highest growth rate, driven by the global epidemic of Type 2 diabetes, escalating healthcare costs associated with poor glycemic control, and compelling clinical evidence for digital therapeutic lifestyle intervention effectiveness. Continuous glucose monitoring integration with behavioral coaching platforms is generating new connected care product categories. Payers are increasingly recognizing the cost savings from digitally managed diabetes populations, expanding coverage policies and driving prescription volume growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to established FDA de novo and 510(k) regulatory pathways for software medical devices, high chronic disease prevalence driving payer interest, and robust venture capital investment in digital health platforms. U.S.-based digital therapeutics companies including Pear Therapeutics and Akili Interactive Labs pioneered commercial prescription models. Employer health benefits integration and large health system adoption programs sustain dominant regional demand.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding smartphone penetration creating platform accessibility infrastructure, growing national digital health investment programs in Japan and South Korea, and vast chronic disease patient populations in China and India. Government digital health mandates and national chronic disease management programs across Asia Pacific markets are incentivizing digital therapeutic adoption at healthcare system level, generating substantial volume growth.

Key players in the market

Some of the key players in Digital Therapeutics Platforms Market include Pear Therapeutics, Omada Health, Livongo Health, Teladoc Health, Propeller Health, Akili Interactive Labs, Click Therapeutics, Better Therapeutics, Kaia Health, Noom Inc., Happify Health, Voluntis, Biofourmis, WellDoc Inc., DarioHealth Corp., ResMed Inc., Philips Healthcare, and Medtronic plc.

Key Developments:

In March 2026, Omada Health announced a major health plan partnership to deliver digital diabetes prevention and management programs across 2 million covered members.

In February 2026, ResMed Inc. expanded its digital therapeutic sleep management portfolio through acquisition of a behavioral insomnia therapy platform with FDA breakthrough status.

In January 2026, Akili Interactive Labs received expanded FDA clearance for its gaming-based cognitive therapy platform addressing adult ADHD beyond the initial pediatric indication approval.

Product Types Covered:

  • Software-based Therapeutics
  • Mobile App-based Therapeutics
  • Web-based Platforms
  • Wearable-integrated Therapeutics
  • Gaming-based Therapeutics
  • VR/AR Therapeutics
  • Other Product Types

Indications Covered:

  • Diabetes Management
  • Mental Health Disorders
  • Cardiovascular Diseases
  • Respiratory Diseases
  • Substance Use Disorders
  • Neurological Disorders

Technologies Covered:

  • AI & Machine Learning
  • Cloud Computing
  • Big Data Analytics
  • IoT Integration
  • Blockchain for Data Security
  • Predictive Analytics

Applications Covered:

  • Treatment & Management
  • Preventive Care
  • Rehabilitation
  • Chronic Disease Management
  • Behavioral Therapy
  • Remote Monitoring
  • Other Applications

End Users Covered:

  • Patients
  • Healthcare Providers
  • Payers
  • Employers
  • Pharmaceutical Companies
  • Research Organizations
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-110 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Digital Therapeutics Platforms Market, By Product Type

  • 5.1 Software-based Therapeutics
  • 5.2 Mobile App-based Therapeutics
  • 5.3 Web-based Platforms
  • 5.4 Wearable-integrated Therapeutics
  • 5.5 Gaming-based Therapeutics
  • 5.6 VR/AR Therapeutics
  • 5.7 Other Product Types

6 Global Digital Therapeutics Platforms Market, By Indication

  • 6.1 Diabetes Management
  • 6.2 Mental Health Disorders
  • 6.3 Cardiovascular Diseases
  • 6.4 Respiratory Diseases
  • 6.5 Substance Use Disorders
  • 6.6 Neurological Disorders

7 Global Digital Therapeutics Platforms Market, By Technology

  • 7.1 AI & Machine Learning
  • 7.2 Cloud Computing
  • 7.3 Big Data Analytics
  • 7.4 IoT Integration
  • 7.5 Blockchain for Data Security
  • 7.6 Predictive Analytics

8 Global Digital Therapeutics Platforms Market, By Application

  • 8.1 Treatment & Management
  • 8.2 Preventive Care
  • 8.3 Rehabilitation
  • 8.4 Chronic Disease Management
  • 8.5 Behavioral Therapy
  • 8.6 Remote Monitoring
  • 8.7 Other Applications

9 Global Digital Therapeutics Platforms Market, By End User

  • 9.1 Patients
  • 9.2 Healthcare Providers
  • 9.3 Payers
  • 9.4 Employers
  • 9.5 Pharmaceutical Companies
  • 9.6 Research Organizations
  • 9.7 Other End Users

10 Global Digital Therapeutics Platforms Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Pear Therapeutics
  • 13.2 Omada Health
  • 13.3 Livongo Health
  • 13.4 Teladoc Health
  • 13.5 Propeller Health
  • 13.6 Akili Interactive Labs
  • 13.7 Click Therapeutics
  • 13.8 Better Therapeutics
  • 13.9 Kaia Health
  • 13.10 Noom Inc.
  • 13.11 Happify Health
  • 13.12 Voluntis
  • 13.13 Biofourmis
  • 13.14 WellDoc Inc.
  • 13.15 DarioHealth Corp.
  • 13.16 ResMed Inc.
  • 13.17 Philips Healthcare
  • 13.18 Medtronic plc

List of Tables

  • Table 1 Global Digital Therapeutics Platforms Market Outlook, By Region (2023-2034)($MN)
  • Table 2 Global Digital Therapeutics Platforms Market Outlook, By Product Type (2023-2034)($MN)
  • Table 3 Global Digital Therapeutics Platforms Market Outlook, By Software-based Therapeutics (2023-2034)($MN)
  • Table 4 Global Digital Therapeutics Platforms Market Outlook, By Mobile App-based Therapeutics (2023-2034)($MN)
  • Table 5 Global Digital Therapeutics Platforms Market Outlook, By Web-based Platforms (2023-2034)($MN)
  • Table 6 Global Digital Therapeutics Platforms Market Outlook, By Wearable-integrated Therapeutics (2023-2034)($MN)
  • Table 7 Global Digital Therapeutics Platforms Market Outlook, By Gaming-based Therapeutics (2023-2034)($MN)
  • Table 8 Global Digital Therapeutics Platforms Market Outlook, By VR/AR Therapeutics (2023-2034)($MN)
  • Table 9 Global Digital Therapeutics Platforms Market Outlook, By Other Product Types (2023-2034)($MN)
  • Table 10 Global Digital Therapeutics Platforms Market Outlook, By Indication (2023-2034)($MN)
  • Table 11 Global Digital Therapeutics Platforms Market Outlook, By Diabetes Management (2023-2034)($MN)
  • Table 12 Global Digital Therapeutics Platforms Market Outlook, By Mental Health Disorders (2023-2034)($MN)
  • Table 13 Global Digital Therapeutics Platforms Market Outlook, By Cardiovascular Diseases (2023-2034)($MN)
  • Table 14 Global Digital Therapeutics Platforms Market Outlook, By Respiratory Diseases (2023-2034)($MN)
  • Table 15 Global Digital Therapeutics Platforms Market Outlook, By Substance Use Disorders (2023-2034)($MN)
  • Table 16 Global Digital Therapeutics Platforms Market Outlook, By Neurological Disorders (2023-2034)($MN)
  • Table 17 Global Digital Therapeutics Platforms Market Outlook, By Technology (2023-2034)($MN)
  • Table 18 Global Digital Therapeutics Platforms Market Outlook, By AI & Machine Learning (2023-2034)($MN)
  • Table 19 Global Digital Therapeutics Platforms Market Outlook, By Cloud Computing (2023-2034)($MN)
  • Table 20 Global Digital Therapeutics Platforms Market Outlook, By Big Data Analytics (2023-2034)($MN)
  • Table 21 Global Digital Therapeutics Platforms Market Outlook, By IoT Integration (2023-2034)($MN)
  • Table 22 Global Digital Therapeutics Platforms Market Outlook, By Blockchain for Data Security (2023-2034)($MN)
  • Table 23 Global Digital Therapeutics Platforms Market Outlook, By Predictive Analytics (2023-2034)($MN)
  • Table 24 Global Digital Therapeutics Platforms Market Outlook, By Application (2023-2034)($MN)
  • Table 25 Global Digital Therapeutics Platforms Market Outlook, By Treatment & Management (2023-2034)($MN)
  • Table 26 Global Digital Therapeutics Platforms Market Outlook, By Preventive Care (2023-2034)($MN)
  • Table 27 Global Digital Therapeutics Platforms Market Outlook, By Rehabilitation (2023-2034)($MN)
  • Table 28 Global Digital Therapeutics Platforms Market Outlook, By Chronic Disease Management (2023-2034)($MN)
  • Table 29 Global Digital Therapeutics Platforms Market Outlook, By Behavioral Therapy (2023-2034)($MN)
  • Table 30 Global Digital Therapeutics Platforms Market Outlook, By Remote Monitoring (2023-2034)($MN)
  • Table 31 Global Digital Therapeutics Platforms Market Outlook, By Other Applications (2023-2034)($MN)
  • Table 32 Global Digital Therapeutics Platforms Market Outlook, By End User (2023-2034)($MN)
  • Table 33 Global Digital Therapeutics Platforms Market Outlook, By Patients (2023-2034)($MN)
  • Table 34 Global Digital Therapeutics Platforms Market Outlook, By Healthcare Providers (2023-2034)($MN)
  • Table 35 Global Digital Therapeutics Platforms Market Outlook, By Payers (2023-2034)($MN)
  • Table 36 Global Digital Therapeutics Platforms Market Outlook, By Employers (2023-2034)($MN)
  • Table 37 Global Digital Therapeutics Platforms Market Outlook, By Pharmaceutical Companies (2023-2034)($MN)
  • Table 38 Global Digital Therapeutics Platforms Market Outlook, By Research Organizations (2023-2034)($MN)
  • Table 39 Global Digital Therapeutics Platforms Market Outlook, By Other End Users (2023-2034)($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.